PharmaEssentia Corporation
6446
Rankning i aktier
#1450
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktiekurs
$35.96
Marknadsvärde
$14.87B
Förändring (1 dag)
-0.85%
Förändring (1 år)
138.77%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Aktiekurshistorik för PharmaEssentia Corporation (6446)
Högsta slutkurs: $37.51 den 2026-10-01
Lägsta slutkurs: $4.95 den 2014-03-01
Lägsta slutkurs: $4.95 den 2014-03-01
Aktiekurshistorik för PharmaEssentia Corporation från 2014 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $165.31 | 23.62% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $224.81 | 31.28% |
CH
|
|
| $18.43 | -4.03% |
IN
|
